Chemo-omic of Anti-Alzheimer Drugs for Novel target identification and biomarker development

Alzheimer's disease is the most common form of dementia. It is expected that 1 in 5 people in the Netherlands will develop dementia in the future, but there are still no effective treatments. Researchers aim to develop such treatments. Multiple processes are involved in Alzheimer's disease, such as the clustering of amyloid and tau proteins, as well as inflammatory reactions in the brain.


The researchers argue that all these processes must be stopped to slow down the disease. They have discovered new drugs that can halt these processes. These drugs will be investigated in this project.


Scientists will achieve this by studying existing data collections and conducting new experiments. They will develop biomarkers to measure the effects of the drugs in patients.

Expected Results

This project will provide evidence for the application of these new molecules. Additionally, the project will lead to the optimization of drug development for Alzheimer's disease.


Project number:
Duration: 1%
Duration: 1 %
Related funding round:
Project lead and secretary:
prof. dr. ing. C.E. Teunissen